Actively Recruiting
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
Led by Siriraj Hospital · Updated on 2024-12-27
240
Participants Needed
1
Research Sites
315 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with myeloproliferative neoplasm (MPN) could have laboratory aspirin resistance and then increasing dose of aspirin from once daily to twice daily regimen is suggested. However, it is not routinely recommended to perform platelet function testing to determine aspirin resistance in MPN patients. Moreover, it is not known whether increasing dose of aspirin would always correct aspirin resistance and significantly prevent the thrombotic events in MPN patients. Therefore, this study aims to compare the efficacy of once daily versus twice daily aspirin in high-risk MPN patients with aspirin resistance. MPN patients with laboratory aspirin resistance will be included in this prospective randomized study and platelet function testing will be repeated at one and six months later. Clinical thrombosis and side effect from aspirin will be recorded for at least 2 years after intervention.
CONDITIONS
Official Title
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Philadelphia-negative myeloproliferative neoplasm patients aged 18 years or older
- Currently taking aspirin at 81 mg per day
- Laboratory confirmed aspirin resistance by light transmission aggregometry (LTA) method
You will not qualify if you...
- Having other active cancer or cured of cancer less than 6 months ago
- Platelet count less than 50,000 per microliter
- Receiving anticoagulant treatment
- Active peptic ulcer
- Active bleeding or planning a procedure with bleeding risk
- No laboratory aspirin resistance detected by LTA method
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital
Bangkok Noi, Bangkok, Thailand, 10700
Actively Recruiting
Research Team
Y
Yingyong Chinthammitr, MD, RCPT, Thai board of hemato
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here